miRagen Therapeutics


miRagen Therapeutics is developing innovative microRNA-based therapeutics for cardiovascular and muscle disease.
CO-INVESTOR
OUTCOME:
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED) Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline
Read moremiRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced incremental new data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in adult T-cell leukemia/lymphoma (ATLL) in an oral presentation at the 19th International Congress HTLV 2019, which is being held from April 24 – 26, 2019, in Lima, Peru.
Read moremiRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2018.
Read more